Earlier this summer, Russian Health Minister Mikhail Murashko clued in a Russian news agency that the first results of a preclinical study of an anti-cancer vaccine would be released late 2024, and those results came back with a positive result. The vaccine was developed as a whole by numerous teams of scientists that represented the Gamaleya National Research Center of Epidemiology and Microbiology, Blokhin Cancer Research Center, and Hertsen Moscow Oncology Research Institute.

Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology exemplified the utilization of AI in advancing and being the catalyst in the vaccine production. Neural network computations powered by artificial intelligence consolidated the necessary time needed into under an hour in creating personalized cancer vaccines.

"Now it takes quite long to build personalized vaccines because computing how a vaccine, or customized mRNA, should look like uses matrix methods, in mathematical terms. We have involved the Ivannikov Institute which will rely on AI in doing this math, namely neural network computing where these procedures should take about half an hour to an hour," Gintsburg stated.

Russia is not the solo ship in this avenue developing a vaccine for cancer, there are also talks of companies such as Merck, BioNTech, CureVac, and Moderna who are also in the field developing a successful vaccine. Leveraging AI and pre-clinical success, the mRNA cancer vaccine is a success in combating and pacifying tumors and metastases, the rapid spread of cancer cells in the cuerpo.

Of course there is skepticism about the success of the vaccine, skeptic scientists such as Professor Kingston Mills, a distinguished immunologist at Trinity College Dublin, Ireland who mentions, "There's nothing in scientific journals that I can see about it. That's where you usually would start reading, as a scientist, about a breakthrough. I don't see any paper about this, so I have nothing to go on in terms of what the science is."

Mills also critiqued the development, with his sceptic with good reason comments stating,

""I think what doesn't make sense is a vaccine for cancer -- as we all know there are multiple cancers," examines Mills. "So, is this a universal vaccine for all cancers? I'd be very skeptical of that. I think it couldn't be. I don't think even the Russians would claim that they have a vaccine to treat all cancers."

With good reason, Mills questions,

"What is the cancer? What is the antigen? Where is the clinical trial data? These are all unanswered questions, and we haven't seen any of this data to make a proper assessment of it."

This miracle will be made available to patients free of cost by 2025, now whether citizens of our great country will be eligible to receive this vaccine, is obviously still in question or discussion one should presume.